147 related articles for article (PubMed ID: 28961664)
1. CNS Drug Development: Lessons Learned Part 3: Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field.
Preskorn SH
J Psychiatr Pract; 2017 Sep; 23(5):352-360. PubMed ID: 28961664
[TBL] [Abstract][Full Text] [Related]
2. CNS drug development: part III: future directions.
Preskorn SH
J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894
[TBL] [Abstract][Full Text] [Related]
3. CNS drug development. Part I: The early period of CNS drugs.
Preskorn SH
J Psychiatr Pract; 2010 Sep; 16(5):334-9. PubMed ID: 20859110
[TBL] [Abstract][Full Text] [Related]
4. CNS drug development: Part II: Advances from the 1960s to the 1990s.
Preskorn SH
J Psychiatr Pract; 2010 Nov; 16(6):413-5. PubMed ID: 21107146
[TBL] [Abstract][Full Text] [Related]
5. [Psychopharmacotherapy in the 20th century].
Siepmann M; Kirch W
Wien Med Wochenschr; 2001; 151(15-17):397-402. PubMed ID: 11603211
[TBL] [Abstract][Full Text] [Related]
6. CNS drug development: lessons learned part 2. Symptoms, not syndromes as targets consistent with the NIMH research domain approach.
Preskorn SH
J Psychiatr Pract; 2015 Jan; 21(1):60-6. PubMed ID: 25603452
[TBL] [Abstract][Full Text] [Related]
7. CNS Drug Development, Lessons Learned, Part 4: The Role of Brain Circuitry and Genes-Tasimelteon as an Example.
Preskorn SH
J Psychiatr Pract; 2017 Nov; 23(6):425-430. PubMed ID: 29303950
[TBL] [Abstract][Full Text] [Related]
8. CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Preskorn SH
J Psychiatr Pract; 2014 Nov; 20(6):460-5. PubMed ID: 25406050
[TBL] [Abstract][Full Text] [Related]
9. Toward standardized usage of the word serendipity in the historiography of psychopharmacology.
Baumeister AA; Hawkins MF; López-Muñoz F
J Hist Neurosci; 2010 Jul; 19(3):253-70. PubMed ID: 20628954
[TBL] [Abstract][Full Text] [Related]
10. Back to the future of psychopharmacology: A perspective on animal models in drug discovery.
Hendriksen H; Groenink L
Eur J Pharmacol; 2015 Jul; 759():30-41. PubMed ID: 25814259
[TBL] [Abstract][Full Text] [Related]
11. The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains.
de Mooij-van Malsen AJ; Pjetri E; Kas MJ
Eur J Pharmacol; 2015 Apr; 753():135-9. PubMed ID: 25107283
[TBL] [Abstract][Full Text] [Related]
12. [The origin of a differentiated neuropsychopharmacotherapy for children and adolescents: an analysis of psycho- and neuropharmacology in the 1940s and 50s].
Gerhard UJ; Schönberg A
Z Kinder Jugendpsychiatr Psychother; 2016; 44(4):285-94. PubMed ID: 27058833
[TBL] [Abstract][Full Text] [Related]
13. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson PH; Clark JA; Cross AJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
[TBL] [Abstract][Full Text] [Related]
14. Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology.
Grabb MC; Gobburu JVS
Prog Neurobiol; 2017 May; 152():38-57. PubMed ID: 27216638
[TBL] [Abstract][Full Text] [Related]
15. Translational PET imaging research.
Hargreaves RJ; Rabiner EA
Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric specialty training in Greece.
Margariti M; Kontaxakis V; Ploumpidis D
Psychiatriki; 2017; 28(1):15-18. PubMed ID: 28541234
[TBL] [Abstract][Full Text] [Related]
17. Mind how you go.
Nature; 2013 Oct; 502(7470):141. PubMed ID: 24137753
[No Abstract] [Full Text] [Related]
18. Future viable models of psychiatry drug discovery in pharma.
Rizzo SJ; Edgerton JR; Hughes ZA; Brandon NJ
J Biomol Screen; 2013 Jun; 18(5):509-21. PubMed ID: 23392517
[TBL] [Abstract][Full Text] [Related]
19. Challenges in developing drugs for neurological and psychiatric disorders.
Simon NG; Brownstein MJ
Prog Neurobiol; 2017 May; 152():1-2. PubMed ID: 28442128
[No Abstract] [Full Text] [Related]
20. Mysteries of the brain. Why is mental illness so hard to treat?
Miller G
Science; 2012 Oct; 338(6103):32-3. PubMed ID: 23042865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
